Who are Copegus (ribavirin)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lonsurf, Dendrid, Ribavirin (R), VAL, Valganciclovir/Ganciclovir, Ribavirin in Arm 1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/copegus-ribavirin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Copegus (ribavirin) — Competitive Intelligence Brief

Copegus (ribavirin) (Copegus (ribavirin)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog antiviral. Area: Virology/Infectious Disease.

marketed Nucleoside analog antiviral Viral RNA polymerase; IMPDH (inosine monophosphate dehydrogenase) Virology/Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Copegus (ribavirin) (Copegus (ribavirin)) — Hoffmann-La Roche. Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with the viral polymerase and depleting guanosine nucleotide pools.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Copegus (ribavirin) TARGET	Copegus (ribavirin)	Hoffmann-La Roche	marketed	Nucleoside analog antiviral	Viral RNA polymerase; IMPDH (inosine monophosphate dehydrogenase)
Lonsurf	TIPIRACIL	Taiho Oncology Inc	marketed	Nucleoside Analog Antiviral [EPC]	Thymidine phosphorylase	2015-01-01
Dendrid	IDOXURIDINE	Novartis	marketed	Nucleoside Analog Antiviral	Thymidine kinase, cytosolic	1963-01-01
Ribavirin (R)	Ribavirin (R)	Tibotec Pharmaceuticals, Ireland	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; guanosine triphosphate metabolism
VAL	VAL	Estetra	marketed	Nucleoside analog antiviral	Cytomegalovirus (CMV) DNA polymerase
Valganciclovir/Ganciclovir	Valganciclovir/Ganciclovir	University Health Network, Toronto	marketed	Nucleoside analog antiviral	Cytomegalovirus (CMV) DNA polymerase
Ribavirin in Arm 1	Ribavirin in Arm 1	MinaPharm Pharmaceuticals	marketed	Nucleoside analog antiviral	Viral RNA polymerase; IMPDH (inosine monophosphate dehydrogenase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-09-22 — Lonsurf · RE46284 · US
2034-06-17 — Lonsurf · 10457666 · US
2034-06-17 — Lonsurf · 9527833 · US
2034-09-05 — Lonsurf · 9943537 · US
2037-02-03 — Lonsurf · 10456399 · US
2037-02-03 — Lonsurf · 10960004 · US

Sponsor landscape (Nucleoside analog antiviral class)

Merck Sharp & Dohme LLC · 3 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Göteborg University · 2 drugs in this class
Estetra · 1 drug in this class
Padagis LLC · 1 drug in this class
MinaPharm Pharmaceuticals · 1 drug in this class
French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
NYU Langone Health · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Ain Shams University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Copegus (ribavirin) — Competitive Intelligence Brief. https://druglandscape.com/ci/copegus-ribavirin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab